Macrophage membrane-coated nanoparticles for the treatment of infectious diseases
Biomedical Materials,
Год журнала:
2024,
Номер
19(4), С. 042003 - 042003
Опубликована: Май 13, 2024
Abstract
Infectious
diseases
severely
threaten
human
health,
and
traditional
treatment
techniques
face
multiple
limitations.
As
an
important
component
of
immune
cells,
macrophages
display
unique
biological
properties,
such
as
biocompatibility,
immunocompatibility,
targeting
specificity,
immunoregulatory
activity,
play
a
critical
role
in
protecting
the
body
against
infections.
The
macrophage
membrane-coated
nanoparticles
not
only
maintain
functions
inner
but
also
inherit
characteristics
macrophages,
making
them
excellent
tools
for
improving
drug
delivery
therapeutic
implications
infectious
(IDs).
In
this
review,
we
describe
their
advantages
challenges
ID
therapy.
We
first
summarize
pathological
features
IDs,
providing
insight
into
how
to
fight
them.
Next,
focus
on
classification,
characteristics,
preparation
nanoparticles.
Finally,
comprehensively
progress
combating
including
delivery,
inhibition
killing
pathogens,
modulation.
At
end
look
forward
aspect
is
presented.
Язык: Английский
CISD2 downregulation participates in the ferroptosis process of human ovarian SKOV-3 cells through modulating the wild type p53-mediated GLS2/SAT1/SLC7A11 and Gpx4/TRF signaling pathway
Tissue and Cell,
Год журнала:
2024,
Номер
89, С. 102458 - 102458
Опубликована: Июль 2, 2024
Язык: Английский
A Mitochondria‐Related Signature in Diffuse Large B‐Cell Lymphoma: Prognosis, Immune and Therapeutic Features
Cancer Medicine,
Год журнала:
2025,
Номер
14(2)
Опубликована: Янв. 1, 2025
ABSTRACT
Background
Distinctive
heterogeneity
characterizes
diffuse
large
B‐cell
lymphoma
(DLBCL),
one
of
the
most
frequent
types
non‐Hodgkin's
lymphoma.
Mitochondria
have
been
demonstrated
to
be
closely
involved
in
tumorigenesis
and
progression,
particularly
DLBCL.
Objective
The
purposes
this
study
were
identify
prognostic
mitochondria‐related
genes
(MRGs)
DLBCL,
develop
a
risk
model
based
on
MRGs
machine
learning
algorithms.
Methods
Transcriptome
profiles
clinical
information
obtained
from
Gene
Expression
Omnibus
(GEO)
database.
was
defined
using
Least
Absolute
Shrinkage
Selection
Operator
(Lasso)
regression
algorithm,
its
value
further
examined
independent
datasets.
Patients
stratified
into
two
clusters
scores,
additionally
nomogram
generated
score
characteristics.
pathway
level,
microenvironment,
expression
targeted
therapy‐associated
genes,
response
immunotherapy,
drug
sensitivity,
somatic
mutation
status
compared
between
clusters.
Results
Eighteen
(DNM1L,
PUSL1,
CHCHD4,
COX7A1,
CPT1A,
CYP27A1,
POLDIP2,
PCK2,
MRPL2,
PDK3,
PDK4,
MARC2,
ACSM3,
COA7,
THNSL1,
ATAD3B,
C15orf48,
TOMM70A)
identified
construct
model.
Remarkable
discrepancies
observed
groups.
high‐risk
group
had
shorter
overall
survival,
less
immune
infiltration,
lower
CD20
higher
PD‐L1
than
low‐risk
group.
Distinct
responses
immunotherapy
predictive
IC50
values
found
Conclusions
We
established
novel
signature
by
which
also
outstanding
tumor
microenvironment
therapies.
Язык: Английский
Should we use nomograms for risk predictions in diffuse large B cell lymphoma patients? A systematic review
Critical Reviews in Oncology/Hematology,
Год журнала:
2024,
Номер
196, С. 104293 - 104293
Опубликована: Фев. 10, 2024
Models
based
on
risk
stratification
are
increasingly
reported
for
Diffuse
large
B
cell
lymphoma
(DLBCL).
Due
to
a
rising
interest
in
nomograms
cancer
patients,
we
aimed
review
and
critically
appraise
prognostic
models
DLBCL
patients.
A
literature
search
PubMed/Embase
identified
59
articles
that
proposed
by
combining
parameters
of
(e.g.,
clinical,
laboratory,
immunohistochemical,
genetic)
between
January
2000
2024.
Of
them,
40
studies
different
gene
expression
signatures
incorporated
them
into
nomogram-based
models.
Although
most
assessed
discrimination
calibration
when
developing
the
model,
many
lacked
external
validation.
Current
mainly
developed
from
publicly
available
databases,
lack
validation,
have
no
applicability
clinical
practice.
However,
they
may
be
helpful
individual
patient
counseling,
although
careful
considerations
should
made
regarding
model
development
due
possible
limitations
choosing
prognostication.
Язык: Английский
Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Ноя. 13, 2024
Background
CDGSH
iron-sulfur
domain
2
(CISD2),
an
protein
with
a
[2Fe-2S]
cluster,
plays
pivotal
role
in
the
progression
of
various
cancers,
including
Diffuse
Large
B-cell
Lymphoma
(DLBCL).
However,
mechanisms
by
which
CISD2
regulates
occurrence
and
development
DLBCL
remain
to
be
fully
elucidated.
Methods
The
potential
as
predictive
marker
patients
treated
R-CHOP
regimen
was
investigated
through
bioinformatics
analysis
clinical
cohort
studies.
cell
lines
(SUDHL-4
HBL-1)
were
employed
this
research.
Adenoviral
(AV)
plasmids
used
either
silence
or
overexpress
these
lines.
Additionally,
induction
ferroptosis
assessed.
Various
parameters,
proliferation,
intracellular
free
iron
levels,
lipid
peroxides,
reactive
oxygen
species
(ROS),
mitochondrial
membrane
(MMP),
measured.
Furthermore,
expression
proteins
associated
ferritinophagy
analyzed.
Drug-resistant
developed
gradually
increasing
doxorubicin
(DOX)
concentration
over
6
months.
biological
drug-resistant
subsequently
Results
Elevated
levels
found
decreased
sensitivity
regimen,
indicated
analysis.
Silencing
significantly
reduced
increased
accumulation,
depleted
glutathione
(GSH),
elevated
malondialdehyde
(MDA)
alongside
accumulation
ROS
MMP.
BECN1
NCOA4
expressions
upregulated,
while
p62,
FTH1,
GPX4
downregulated.
Conversely,
overexpression
reversed
effects.
Treatment
Erastin
led
levels.
Notably,
lines,
knockdown
promoted
ferritinophagy,
restoring
DOX
enhancing
efficacy
treatment.
Conclusion
Our
findings
suggest
that
may
play
drug
resistance
observed
patients.
Inhibition
could
enhance
potentially
improving
cells
Язык: Английский
Inhibition of CDGSH iron‑sulfur domain 2 exhibits tumor-suppressing effects on diffuse large B-cell lymphoma (DLBCL) by inducing ferroptosis through the regulation of the NRF2/SLC7A11/GPX4 pathway
Toxicology and Applied Pharmacology,
Год журнала:
2024,
Номер
493, С. 117148 - 117148
Опубликована: Ноя. 8, 2024
Язык: Английский